Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO Listing Day Performance
Symbiotec Pharmalab listed on BSE & NSE on 01 September 2026 at ₹988.00, a 0% premium over the issue price of ₹988. A retail investor allotted one lot of 15 shares gained ₹0 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹185 (+18.7%) |
| GMP-implied listing | ₹1,173 |
| Actual listing | ₹988.00 |
| Difference | −₹185 (−15.8%) |
Demand going into listing
| Subscribed overall | 75.05× |
| QIB | 181.2× |
| NII | 77.56× |
| Retail | 13.64× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 3 | Day 4 |
|---|---|---|---|---|
| QIB | 0.35x | 0.54x | 0.59x | 181.20x |
| NII | 1.04x | 3.00x | 12.18x | 77.56x |
| bNII > ₹10L | 0.78x | 2.46x | 11.30x | 87.34x |
| sNII 2-10L | 1.58x | 4.08x | 13.95x | 58.00x |
| Retail | 0.95x | 2.10x | 5.05x | 13.64x |
| Employee | 1.56x | 3.01x | 5.86x | 16.31x |
| Total | 0.80x | 1.85x | 5.31x | 75.05x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 723.33 | 755.98 | 872.26 |
| Expense | 590.99 | 608.85 | 709.90 |
| Profit (PAT) | 100.06 | 96.79 | 109.90 |
| Total Assets | 1,294.79 | 1,579.65 | 1,780.79 |
Peer Comparison
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Symbiotec Pharmalab This IPO | 19.10 | - | 9.48 | 184.69 | - |
| Concord Biotech Limited | 24.78 | 61.07 | 14.00 | - | 1,054.90 Cr |
| Divi’s Laboratories Limited | 96.75 | 87.80 | 16.50 | 631.00 | 10,560.00 Cr |
| Cohance Lifesciences Limited | 4.69 | 95.02 | 7.00 | - | 2,268.55 Cr |
| Laurus Labs Limited | 16.47 | 109.36 | 16.80 | - | 6,812.90 Cr |
Strengths & Risks
- Heavily oversubscribed — 75.1x overall (so far).
- Strong institutional (QIB) demand — 181.2x.
- Revenue grew 15% in the latest reported year.
- Solid profit margin — 12.6%.
- Largely an offer for sale — most proceeds go to selling shareholders, not the company.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Symbiotec Pharmalab at a glance
From the company's description: “Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience.”
Symbiotec Pharmalab is raising ₹1,757 crore through an IPO on the BSE and NSE mainboard. Of that, ₹150 crore is a fresh issue — new shares, with the money going to the company — and ₹1,607 crore is an offer for sale by existing shareholders, who keep those proceeds; 8.5% of the issue therefore reaches the business. Main stated uses of the fresh money: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company (₹113 crore).
Revenue went from ₹723 crore in 2024 to ₹872 crore in 2026, up 21% over 2 years. Profit after tax went from ₹100 crore to ₹110 crore, a net margin of 13% in the latest year.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Symbiotec Pharmalab Ltd., 385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| General corporate purposes | - |
Resources & Documents
Anchor Investors
Symbiotec Pharmalab IPO - Quick Take
Symbiotec Pharmalab has set a price band of Rs 938–Rs 988 per share for an issue size of Rs 1,757 crore. The stock listed flat against its issue price.
The issue is promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP with JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Co… (Rs 113 crore) and general corporate purposes.
On fundamentals, the company is posting revenue growth of 15.4%, a profit margin of 12.6%, return on equity of 11.2% in its most recent reported period. Listed peers in this segment include Concord Biotech Limited (P/E 61.07x) and Divi’s Laboratories Limited (P/E 87.80x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Symbiotec Pharmalab IPO: Lead Manager & Registrar Track Record
How the firms running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Symbiotec Pharmalab itself, so they describe what came before it.
- Symbiotec Pharmalab listed at +0% on day one; the median of 113 listings was +7% (better than 21% of them).
- Subscribed 75.05x against a median of 20.43x across 111 issues (higher than 74%).
- Average listing-day move across all 114 Mainboard listings we track: +13.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| JM Financial Ltd. Lead manager | 32 32 MB · 0 SME | 86% 24 of 28 | +16% | +6.1% |
| Avendus Capital Pvt. Ltd. Lead manager | 6 6 MB · 0 SME | 83% 5 of 6 | +3.3% | +4.9% |
| Motilal Oswal Investment Advisors Ltd. Lead manager | 20 20 MB · 0 SME | 84% 16 of 19 | +11.7% | +7% |
| Nomura Financial Advisory & Securities (India) Pvt. Ltd. Lead manager | 2 2 MB · 0 SME | 50% 1 of 2 | +14.5% | +14.5% |
| MUFG Intime India Pvt. Ltd. Registrar | 66 44 MB · 22 SME | 74% 46 of 62 | Check allotment → | |
Recent listings managed by JM Financial Ltd. (5)
Best: Tempsens Instruments +111.3% · Weakest: Turtlemint Fintech −11.3%
| IPO | Listed | Listing-day move |
|---|---|---|
| SFC Environmental | 03 Nov 2026 | +7.6% |
| Jio Platforms | 28 Oct 2026 | +21.4% |
| Paras Healthcare | 28 Oct 2026 | +3.9% |
| Zetwerk | 23 Oct 2026 | +5.5% |
| Tonbo Imaging | 23 Oct 2026 | +66% |
Recent listings managed by Avendus Capital Pvt. Ltd. (5)
Best: SEDEMAC Mechatronics +13.5% · Weakest: Amagi Media Labs −12.2%
| IPO | Listed | Listing-day move |
|---|---|---|
| Zetwerk | 23 Oct 2026 | +5.5% |
| Sahajanand Medical | 23 Oct 2026 | +7.9% |
| NSE | 24 Sep 2026 | +0.8% |
| LEAP India | 14 Aug 2026 | +4.3% |
| SEDEMAC Mechatronics | 11 Mar 2026 | +13.5% |
Recent listings managed by Motilal Oswal Investment Advisors Ltd. (5)
Best: CMR Green Technologies +43.4% · Weakest: Waterways Leisure Tourism −15.7%
| IPO | Listed | Listing-day move |
|---|---|---|
| EAAA India Alternatives | 02 Nov 2026 | +0.6% |
| Sahajanand Medical | 23 Oct 2026 | +7.9% |
| Fusion CX | 22 Oct 2026 | +5.5% |
| NSE | 24 Sep 2026 | +0.8% |
| Manipal Payment | 17 Sep 2026 | −2.1% |
Recent listings managed by Nomura Financial Advisory & Securities (India) Pvt. Ltd. (2)
Best: Dhoot Transmission +37.8% · Weakest: Clean Max Enviro −8.8%
| IPO | Listed | Listing-day move |
|---|---|---|
| Dhoot Transmission | 17 Aug 2026 | +37.8% |
| Clean Max Enviro | 02 Mar 2026 | −8.8% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Symbiotec Pharmalab IPO GMP — What It Means
Its last GMP before listing was 18.7%. Of the 26 Mainboard IPOs we have tracked with a final GMP between 10% and 25%, 23 listed above, 2 flat and 1 below the issue price; Symbiotec Pharmalab listed flat.
See the full Symbiotec Pharmalab GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Symbiotec PharmalabNo comments yet. Be the first to share your opinion!